Sclerosis News and Research

RSS

Scientists identify new compound that reverses ALS neuron damage

Northwestern University scientists have identified the first compound that eliminates the ongoing degeneration of upper motor neurons that become diseased and are a key contributor to ALS (amyotrophic lateral sclerosis), a swift and fatal neurodegenerative disease that paralyzes its victims.

23 Feb 2021

Some nutritional supplements may help prevent or mitigate COVID-19 severity

A new study in the Journal of dietary supplements shows that nutritional supplements, including several vitamins and the mineral zinc, may be useful in preventing the infection or reducing its severity if caught.

22 Feb 2021

Researchers discover first evidence of protein folding driven by liquid-liquid phase separation

Scientists have discovered the first evidence of protein folding driven by liquid-liquid phase separation, a phenomenon in which fluids form into microscopic droplets and separate inside cells -- like drops of oil in water.

20 Feb 2021

Companies pan for marketing gold in vaccines

For a decade, Jennifer Crow has taken care of her elderly parents, who have multiple sclerosis. After her father had a stroke in December, the family got serious in its conversations with a retirement community — and learned that one service it offered was covid-19 vaccination.

19 Feb 2021

Researchers measure baseline activity of single neurons

Our brains are complicated webs of billions of neurons, constantly transmitting information across synapses, and this communication underlies our every thought and movement.

18 Feb 2021

Blood-clotting protein linked with tumor pathogenesis of CNS B-cell lymphoma

In people with central nervous system (CNS) lymphoma, cancerous B cells--a type of white blood cell--accumulate to form tumors in the brain or spinal cord, often in close proximity to blood vessels.

17 Feb 2021

Simulating an overactive autoimmune response leads to changes in the brain region

Researchers at the University of Tsukuba in Japan show that simulating an overactive autoimmune response in mice leads to changes in the hippocampal region of the brain.

17 Feb 2021

Research shows how chemicals in the tumor microenvironment enable cancer to evade attack

A paper published today in Nature shows how chemicals in the areas surrounding tumors--known as the tumor microenvironment--subvert the immune system and enable cancer to evade attack. These findings suggest that an existing drug could boost cancer immunotherapy.

15 Feb 2021

Immunosuppressive therapies may be linked to severe COVID-19 in those with multiple sclerosis

A new study examines the associations between immunosuppressive disease-modifying therapies (DMTs) used in MS with adverse outcomes in an international cohort of patients with MS COVID-19.

15 Feb 2021

New technology can help develop diagnostic tests for multiple sclerosis

Multiple sclerosis (MS) is the most common neurological disease in young adults, affecting more than 2 million individuals worldwide, with about 1500 cases in Estonia. About 20% of MS patients experience optic neuritis (ON) as the presenting symptom, but not all ON patients develop MS.

12 Feb 2021

Scientists present new outlook on latest trends in peptide drug discovery and development

Currently there are more than 80 peptide drugs on the global market and about twice as many in clinical development.

10 Feb 2021

Study could help develop drugs for pregnancy maintenance, treat autoimmune diseases

A team of scientists from Immanuel Kant Baltic Federal University with their colleagues from the Institute of Ecology and Genetics of Microorganisms of the Ural Branch of the Russian Academy of Sciences (Perm) studied the effect of trophoblastic β1-glycoprotein in the blood of pregnant women on pro-inflammatory immune cells.

10 Feb 2021

New study to examine the effects of MS disease-modifying therapy on cognitive fatigue

Kessler Foundation researchers have received support from Genentech, a member of the Roche Group, to conduct an investigator-initiated study on the effects of ocrelizumab (Ocrevus) on cognitive fatigue in individuals with relapsing-remitting multiple sclerosis (MS).

8 Feb 2021

Targeted pulses of ultrasound can help treat a range of brain diseases

Ultrasound is not only used as an imaging technique but targeted pulses of ultrasound can be used as a highly accurate treatment for a range of brain diseases, for which there were previously only limited treatment options.

5 Feb 2021

Study shows how genetic mutations lead to kidney cysts in tuberous sclerosis complex

Tuberous sclerosis complex (TSC) afflicts as many as two million people around the world, affecting multiple organs, including lungs, brain, skin and kidneys. In about 80 percent of cases, it causes cysts and benign tumors to form in the kidney, eventually resulting in kidney failure.

5 Feb 2021

Canadian Neuromuscular Disease Registry increases patient access to research, clinical trials

The Canadian Neuromuscular Disease Registry (CNDR) was launched in 2010 to increase efficient patient access to cutting-edge research and clinical trials, to increase understanding of the natural history and epidemiology of neuromuscular disease across Canada, and to facilitate research collaboration.

3 Feb 2021

Remyelinating drug shows potential to improve vision in patients with MS

A team led by a biomedical scientist at the University of California, Riverside, reports a drug -- an estrogen receptor ligand called indazole chloride (IndCl) -- has the potential to improve vision in patients with multiple sclerosis, or MS.

2 Feb 2021

New guidance to provide mental health support for people with neurodegenerative conditions

Lancaster University together with the British Psychological Society has provided research-based recommendations for mental health support for people living with four motor neurodegenerative conditions.

2 Feb 2021

SARS-CoV-2 triggers development of new-onset IgG autoantibodies in hospitalized COVID-19 patients

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent for coronavirus disease 2019 (COVID-19), is associated with several clinical features common in autoimmune diseases as myalgias, arthralgias, fatigue, and rashes. COVID-19 patients also exhibit less common autoimmunity manifestations such as myositis, thrombosis, myocarditis, encephalitis, vasculitis, and arthritis.

1 Feb 2021

Early-life-trauma could affect trajectory of multiple sclerosis development and treatment

Childhood trauma could affect the trajectory of multiple sclerosis development and response to treatment in adulthood, a new study in mice found.

29 Jan 2021